100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double ‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

Headache: The Journal of Head and Face Pain, EarlyView.

Source: Headache: The Journal of Head and Face Pain - October 20, 2018 Category: Neurology Authors: Noah Rosen, Eric Pearlman, Dustin Ruff, Kathleen Day, Abraham Jim Nagy Source Type: research